Formulation batch manufacturing for oral direct compression tablets is one of the most widely adopted and cost-efficient methods in modern pharmaceutical development. Direct compression offers precision, scalability, and regulatory compliance, making it the preferred choice for stability studies, clinical trial batches, and eventual commercial scale-up. In this detailed article, we will outline the objectives, responsibilities, process flow, analytical testing, packaging, stability requirements, transportation, and documentation deliverables that ensure full compliance with cGMP, ICH, and regulatory standards.

Ukraine Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Levofloxacin500 mgTablet10 TabletsAntibiotic (Fluoroquinolone)
Levofloxacin250 mgTablet10 TabletsAntibiotic (Fluoroquinolone)
Ciprofloxacin500 mgTablet30 TabletsAntibiotic (Fluoroquinolone)
Ambroxol30 mgTablet20 TabletsExpectorant/Mucolytic
Amlodipine5 mgTablet20 TabletsAntihypertensive (Calcium Channel Blocker)
Amlodipine10 mgTablet30 TabletsAntihypertensive (Calcium Channel Blocker)
Captopril25 mgTablet20 TabletsAntihypertensive (ACE Inhibitor)
Captopril50 mgTablet20 TabletsAntihypertensive (ACE Inhibitor)
Enalapril10 mgTablet30 TabletsAntihypertensive (ACE Inhibitor)
Enalapril20 mgTablet30 TabletsAntihypertensive (ACE Inhibitor)
Lisinopril10 mgTablet30 TabletsAntihypertensive (ACE Inhibitor)
Pregabalin75 mgCapsule30 CapsulesNeuropathic Pain/Anticonvulsant
Pregabalin150 mgCapsule30 CapsulesNeuropathic Pain/Anticonvulsant
Pregabalin300 mgCapsule30 CapsulesNeuropathic Pain/Anticonvulsant
Xylometazoline0.1%Nasal Drops10 ml BottleNasal Decongestant
Ranitidine150 mgTablet100 TabletsAntiulcer (H2 Blocker)
Ranitidine150 mgTablet20 TabletsAntiulcer (H2 Blocker)
Domperidone10 mgTablet30 TabletsAntiemetic/Prokinetic
Domperidone10 mgTablet60 TabletsAntiemetic/Prokinetic
Simvastatin20 mgTablet30 TabletsLipid-lowering (Statin)
Simvastatin20 mgTablet60 TabletsLipid-lowering (Statin)
Simvastatin40 mgTablet30 TabletsLipid-lowering (Statin)
Simvastatin40 mgTablet60 TabletsLipid-lowering (Statin)
Diclofenac1%Gel30 g TubeNSAID (Topical)
Diclofenac50 mgTablet20 TabletsNSAID (Analgesic)
Diclofenac100 mgTablet20 TabletsNSAID (Analgesic)
Paracetamol + Diclofenac500 mg + 50 mgTablet10 TabletsAnalgesic/Antipyretic + NSAID
Ibuprofen100/5Dry Syrup100 ml BottleNSAID (Analgesic/Antipyretic)
Ibuprofen100/5Dry Syrup200 ml BottleNSAID (Analgesic/Antipyretic)
Ibuprofen200/5Dry Syrup100 ml BottleNSAID (Analgesic/Antipyretic)
Paracetamol500 mgTablet10 TabletsAnalgesic/Antipyretic
Metronidazole250 mgTablet20 TabletsAntiprotozoal/Antibacterial
Carvedilol12.5 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Carvedilol25 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Loperamide2 mgTablet20 TabletsAntidiarrheal
Bisoprolol5 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Bisoprolol10 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Azithromycin500 mgTablet3 TabletsAntibiotic (Macrolide)
Itraconazole100 mgCapsule100 CapsulesAntifungal
Clopidogrel75 mgTablet100 TabletsAntiplatelet
Cefepime1 gInjection (Vial)1 VialAntibiotic (Cephalosporin)
Ceftriaxone1 gInjection (Vial)1 VialAntibiotic (Cephalosporin)
Cefixime400 mgTabletAntibiotic (Cephalosporin)
Risperidone1, 2, 3, 4 mgTabletAntipsychotic
Loperamide2 mgCapsuleAntidiarrheal
Amoxiclav1.2 gInjection (Vial)1 VialAntibiotic (Beta-lactam + Clavulanic acid)

Chile Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Risperidone1 mg, 3 mgTabletAntipsychotic
Lithium Carbonate300 mgTabletMood Stabilizer
Hydroxychloroquine200 mgTabletAntimalarial/Immunomodulator
Ursodeoxycholic AcidTabletHepatoprotective

Costa Rica Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Carbamazepine CR200 mgTablet (CR)Anticonvulsant
Mesalamine1 gSuppositoryAnti-inflammatory (IBD)
Montelukast Sodium5 mgTabletAntiasthmatic (Leukotriene Antagonist)

Philippines Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Labetalol100 mg, 200 mgTabletAntihypertensive (Beta Blocker)
Sumatriptan + Naproxen50 mg + 275 mgTabletAntimigraine
Gabapentin100 mgCapsuleAnticonvulsant/Neuropathic Pain

Objective of Direct Compression Batch Manufacturing

The primary goal of oral direct compression batch manufacturing is to produce clinical, stability, and commercial validation batches with accuracy, reproducibility, and quality assurance. These batches are executed at Contract Manufacturing Organizations (CMOs) under stringent environmental and regulatory conditions. The objectives include:

  • Manufacturing tablets for stability studies, bioequivalence (BE)/pharmacokinetics (PK) trials, and commercial validation.
  • Maintaining compliance with cGMP guidelines, ICH Q8/Q9/Q10, and regulatory authority expectations.
  • Ensuring robustness of formulation to facilitate smooth technology transfer and eventual large-scale production.

Roles and Responsibilities in Batch Manufacturing

Customer Responsibilities

  • Provide an approved manufacturing formula and batch record.
  • Supply API specifications, excipients, and raw materials that meet pharmacopeial standards.
  • Define stability study protocols, product specifications, and testing methodologies.

CMO Responsibilities

  • Apply for required API import licenses and manufacturing approvals.
  • Manufacture the tablets strictly according to the approved master batch record (MBR).
  • Maintain strict environmental controls such as temperature and humidity in GMP areas.
  • Execute packaging, labeling, and stability studies in compliance with BENOC/ICH guidelines.
  • Provide batches for clinical dosing, validation, and commercial evaluation.

Formulation Batch Details

The size and strength of the batches are tailored to the development stage:

  • Pilot Batch (Stability): ~5,000 tablets
  • Clinical Batch: ~50,000 tablets
  • Commercial Validation Batch: 3 × 100,000 tablets

Strengths may vary across single or multiple dose levels. These batches are designated for stability studies, BE/PK trials, and validation activities.


Formulation Process for Direct Compression Tablets

Direct compression eliminates the need for granulation, making the process efficient and reproducible.

Stepwise Flow Chart:

  1. Raw Material Dispensing – Accurate weighing of API and excipients using calibrated balances.
  2. Sifting/Sieving – Removal of lumps and foreign particles to achieve uniform particle size.
  3. Blending – Homogeneous mixing of API with fillers, binders, and disintegrants.
  4. Lubricant Addition – Incorporation of lubricants like magnesium stearate for smooth compression.
  5. Compression – Conversion of blend into tablets using rotary compression machines.
  6. Primary Packaging – Packing into Alu-Alu blister packs under controlled conditions.

Tablet Specifications:

  • Round (6.5 mm or 7 mm)
  • Oval (13 × 7 mm)

Environmental Conditions:

  • Temperature: ≤ 30°C
  • Relative Humidity: 35% RH (up to 40% permissible)

Equipment Required:

  • Calibrated weighing balances
  • Rotary compression machine
  • High-shear or bin blender
  • Packing machine for blister/carton packaging
  • Roller compactor (only if excipients do not meet specifications)

Analytical Testing & Sample Management

Each batch undergoes rigorous analytical testing to ensure safety, efficacy, and compliance.

Key Analytical Tests:

  • Appearance (visual inspection for defects)
  • Assay (HPLC) for API content
  • Content Uniformity across tablets
  • Dissolution profile studies
  • Related Substances (impurities/degradants)
  • Water Content (Karl Fischer titration)
  • Microbial Limits (if applicable)
  • Stability-indicating Parameters

Sample Retention:

  • Stability Samples: Retained as per ICH Q1A guidelines.
  • Reference Samples: Retained for regulatory audits.
  • Retention Samples: Maintained as per GMP documentation requirements.

Packaging Requirements

Proper packaging ensures stability, compliance, and traceability of clinical and commercial batches.

  • Primary Packaging: Alu-Alu blisters (10’s or market-specific configuration).
  • Secondary Packaging: Printed cartons with leaflet inserts.
  • Clinical Labeling: As per IRB/regulatory standards with details such as batch number, storage conditions, expiry date, and usage instructions.
  • Commercial Packaging: Designed as per market-specific artwork and branding guidelines.

Stability Study Plan

Stability testing is essential to establish shelf life and storage conditions.

Conditions:

  • Long-term: 25°C ± 2°C / 60% ± 5% RH
  • Accelerated: 40°C ± 2°C / 75% ± 5% RH
  • Intermediate: 30°C ± 2°C / 65% ± 5% RH

Time Points:

  • 0, 1, 3, 6, 9, 12, 18, 24 months

Parameters Monitored:

  • Assay
  • Dissolution profile
  • Impurity profiling
  • Physical appearance
  • Moisture content
  • Microbial testing (if required)

Transport Requirements

Transport of both API and finished drug product (FDF) requires qualified logistics partners with validated systems.

  • Mode: Temperature-controlled vehicles with qualified couriers.
  • Conditions: API transported at 2–8°C, FDF transported at 15–25°C.
  • Data Logging: Mandatory during every shipment for temperature verification.
  • Packaging: Use of insulated shippers, validated gel packs, or phase change materials.

Documentation Deliverables

Comprehensive documentation is a regulatory prerequisite for every stage of manufacturing.

  • Master Batch Record (MBR) & Batch Manufacturing Record (BMR)
  • Certificates of Analysis (COA) for raw materials and finished products
  • Deviation and CAPA reports
  • Stability study protocols and interim reports
  • Transport validation reports

These deliverables not only ensure regulatory compliance but also facilitate audit readiness and smooth technology transfer.


The process of formulation batch manufacturing for oral direct compression tablets is a highly controlled and regulated activity, critical to pharmaceutical development and commercialization. From pilot and clinical batches to commercial validation, each stage demands robust processes, precise documentation, and compliance with international guidelines. By following best practices in formulation, testing, packaging, stability studies, and transportation, pharmaceutical companies can ensure successful product launches and patient safety worldwide.